Nanotechnology Now - Press Release: CRIXlabs Joins the ROCK Health Incubator: ROCK Health is the world’s leading healthcare incubator looking to make meaningful change through scalable, innovative technology.

Home > Press > CRIXlabs Joins the ROCK Health Incubator: ROCK Health is the world’s leading healthcare incubator looking to make meaningful change through scalable, innovative technology.

Abstract:
CRIXlabs, Inc. today announced joining the ROCK Health incubator located in San Francisco, CA. CRIXlabs is the creator of NuSilico, the #1 predictive nanoparticle software used by Pharma.

CRIXlabs Joins the ROCK Health Incubator: ROCK Health is the world’s leading healthcare incubator looking to make meaningful change through scalable, innovative technology.

San Diego, CA | Posted on June 5th, 2013

"We couldn't be more excited to be part of the family over at ROCK Health" said Jon Stenstrom, CRIXlabs' CEO and Co-Founder. "CRIXlabs' NuSilico software enables pharmaceutical companies to create more effective treatments with reduced side-effects, for cancer and a wide variety of other diseases." Jon has a strong healthcare product development background and holds a Master of Engineering from San Diego State University.

The CRIXlabs team includes Dr. Shalini Ananda, CTO and Co-Founder with expertise in software development and nanotechnology and Dr. Garrett Smith, Co-Founder and advisor, a serial entrepreneur with expertise in nanoparticle synthesis and a former Stanford BioDesign Fellow; both of which received their PhDs from the University of California, San Diego.

The ROCK Health announcement: rockhealth.com/2013/06/new-class-new-partners-new-space/

####

About CRIXlabs, Inc.
Creators of NuSilico, the #1 predictive nanoparticle software used by Pharma.

NuSilico increases the probability of finding the next blockbuster drug. Today, Pharma uses NuSilico to identify unfavorable nanotherapeutic candidates early, potentially saving years of development time and millions of dollars. NuSilico can optimize nanoparticle platforms, increasing their ability to treat diseases such as cancer more effectively and with lower side-effects.

CRIXlab’s unique background in software, nanoparticle synthesis, and imaging helps researchers look at all possible scenarios prior to beginning pre-clinical trials.

NuSilico uses a proprietary database and algorithms to determine the biodistribution and half-life of nanoparticle platforms prior to expensive preclinical trials. Early identification helps ensure the research process is efficient and cost-effective for the client.

CRIXlabs has been accepted into the ROCK Health incubator in San Francisco and have terms on the table with Kleiner Perkins, Mohr Davidow, Aberdare Ventures, and the Mayo Clinic.

They have begun working with a Top 10 Pharmaceutical company on their nanoparticle platforms. They are in active discussions with the Top 5 Pharmaceutical companies for the use of their software.

For more information, please click here

Contacts:
Jon Stenstrom, MEng.
Co-Founder & CEO
CRIXlabs, Inc.
858-598-4272

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: